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Summary
The BCR/ABL oncogene causes chronic myelogenous leukemia (CML) in humans and a CML-like disease, as well as
lymphoid leukemia, in mice. p210 BCR/ABL is an activated tyrosine kinase that phosphorylates itself and several cellular
signaling proteins. The autophosphorylation site tyrosine 177 binds the adaptor Grb2 and helps determine the lineage and
severity of BCR/ABL disease: Tyr177 mutation (BCR/ABL-Y177F) dramatically impairs myeloid leukemogenesis, while
diminishing lymphoid leukemogenesis. The critical signal(s) from Tyr177 has remained unclear. We report that Tyr177
recruits the scaffolding adaptor Gab2 via a Grb2/Gab2 complex. Compared to BCR/ABL-expressing Ba/F3 cells, BCR/ABL-
Y177F cells exhibit markedly reduced Gab2 tyrosine phosphorylation and association of phosphatidylinositol-3 kinase
(PI3K) and Shp2 with Gab2 and BCR/ABL, and decreased PI3K/Akt and Ras/Erk activation, cell proliferation, and spontane-
ous migration. Remarkably, bone marrow myeloid progenitors from Gab2 (/) mice are resistant to transformation by
BCR/ABL, whereas lymphoid transformation is diminished as a consequence of markedly increased apoptosis. BCR/ABL-
evoked PI3K/Akt and Ras/Erk activation also are impaired in Gab2 (/) primary myeloid and lymphoid cells. Our results
identify Gab2 and its associated proteins as key determinants of the lineage and severity of BCR/ABL transformation.
Introduction Shtivelman et al., 1985; Walker et al., 1987). Despite intensive
study, the mechanism underlying the different lineage associa-
Several forms of human leukemia are caused by the Philadelphia tions of the three BCR/ABL proteins remains largely unknown.
chromosome (Ph) translocation [t(9,22) (q34;q11)], which fuses The BCR region of the fusion proteins probably plays a
the BCR and c-ABL genes. Three different translocation major role in specifying both the virulence and the lineage of
breakpoints result in the production of distinct BCR/ABL fusion the leukemia. When introduced into murine bone marrow cells
proteins that share the same segment of c-ABL, but differ in by retroviral transduction followed by bone marrow transplanta-
BCR content. The most common fusion protein, p210 BCR/ tion (BMT), all of the BCR/ABL fusion proteins can cause a
ABL, causes chronic myelogenous leukemia (CML), whereas chronic myeloid leukemia (CML)-like myeloproliferative disease,
p190 BCR/ABL is found primarily in a subset of patients with but p190 BCR/ABL is more potent at inducing lymphoid leuke-
acute lymphocytic leukemia (ALL), and p230 BCR/ABL is found mia (Li et al., 1999; Quackenbush et al., 2000). Recent studies
in chronic neutrophilic leukemia (Ben-Neriah et al., 1986; Chan of BCR/ABL oncogenes with mutations of a single autophos-
phorylation site in BCR, Tyr177, have linked BCR signaling toet al., 1987; Clark et al., 1987; Fainstein et al., 1987; Heisterkamp
et al., 1983, 1985; Kurzrock et al., 1987; Pane et al., 1996; lineage determination and disease latency (Million and Van Et-
S I G N I F I C A N C E
The BCR/ABL oncogene encodes an activated tyrosine kinase that causes myeloid and lymphoid leukemias. Mutation of the
autophosphorylation site at Tyrosine 177 in BCR (BCR/ABL-Y177F) dramatically impairs myeloid leukemogenesis, while diminishing
lymphoid leukemogenesis. We report that Tyr177 recruits the scaffolding adapter Gab2 via a Grb2/Gab2 complex. Cells expressing
BCR/ABL-Y177F exhibit reduced association of PI3K and Shp2 with Gab2 and BCR/ABL, decreased PI3K/Akt and Ras/Erk activation,
and reduced cell proliferation and migration. Remarkably, bone marrow cells from Gab2 (/) mice are highly resistant to myeloid,
and partially resistant to lymphoid transformation by BCR/ABL, most likely as a consequence of increased apoptosis. Our results
identify Gab2 signaling as a key determinant of the lineage and severity of BCR/ABL transformation.
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ten, 2000; Zhang et al., 2001). Tyr177 lies within a Grb2 binding We have found that tyrosine phosphorylation of Gab2 in
BCR/ABL-transformed cells requires Y177 of BCR/ABL and themotif (Y-X-N-X) in BCR, and is essential for Grb2 binding to BCR/
ABL (Pendergast et al., 1993; Puil et al., 1994). The importance of Grb2 SH3 binding site in Gab2; thus, Gab2 phosphorylation by
BCR/ABL is mediated by a Grb2/Gab2 complex. This interactiondirect binding of Grb2 to BCR/ABL has been controversial.
Pendergast et al. reported that p190 BCR/ABL-Y177F is defec- is required for full activation of the PI3K/Akt and Ras/Erk path-
ways and for optimal proliferation and migration of Ba/F3 cellstive for transactivation of a Ras-responsive reporter gene in
Rat-1 fibroblasts, transformation of Rat-1 cells to anchorage- in response to BCR/ABL. More importantly, BCR/ABL cannot
transform primary myeloid cells from Gab2 (/) mice, whereasindependence, and ex vivo transformation of primary bone mar-
row pre-B lymphocytes. These workers concluded that phos- Gab2 (/) B lymphoblasts can be transformed, but exhibit
defective migratory capacity and proliferation. The latter is due,phorylation of Tyr177 was necessary for Ras activation and
BCR/ABL transformation (Pendergast et al., 1993). Consistent at least in large part, to a marked increase in apoptosis. More-
over, primary myeloid and lymphoid cells from Gab2 (/) micewith this hypothesis, expression of a Grb2 SH3 domain domi-
nant-negative mutant (Gishizky et al., 1995) or interference with transduced with BCR/ABL-WT-expressing retroviruses have
comparable signaling defects to Ba/F3 cells expressing BCR/the Ras pathway by expression of activated RasGAP (Sawyers
et al., 1995) or dominant-negative Ras (Cortez et al., 1995; ABL-Y177F. Our results implicate Gab2 as a key mediator of
signals critical for determining the lineage and severity of trans-Sakai et al., 1994) inhibits BCR/ABL transformation. However,
subsequent studies demonstrated that BCR/ABL-Y177F could formation by BCR/ABL.
transform primary B lymphocytes (Goga et al., 1995) and cyto-
kine-dependent hematopoietic cell lines ex vivo (Cortez et al., Results
1995; Goga et al., 1995). Furthermore, unlike in Rat-1 cells, Ras
activation by BCR/ABL-Y177F was normal in hematopoietic cell The Grb2 binding site in BCR/ABL regulates tyrosine
phosphorylation of Gab2lines (Cortez et al., 1995), suggesting that Ras could be activated
through alternative pathways (e.g., via tyrosine phosphorylated The binding site for the Grb2 SH2 domain in BCR/ABL (Tyr177)
regulates multiple aspects of BCR/ABL action, including ex vivoShc) in these cells.
Three recent studies have begun to clarify this controversy. transformation of fibroblasts or pre-B lymphocytes and efficient
proliferation of factor-dependent hematopoietic cell lines (Cor-In the murine bone marrow transduction/transplantation model,
p210 BCR/ABL-Y177F is profoundly defective for induction of tez et al., 1995; Pendergast et al., 1993; Puil et al., 1994), and
the latency and type (i.e., lineage) of leukemia caused by BCR/CML-like myeloproliferative disease; instead, recipients of p210
BCR/ABL-Y177F-transduced marrow succumb to B- and T-lym- ABL in the murine bone marrow transduction/transplantation
model (Million and Van Etten, 2000; Zhang et al., 2001; He etphoid leukemias of prolonged latency (He et al., 2002; Million
and Van Etten, 2000; Zhang et al., 2001). These results demon- al., 2002). To identify signaling defects specifically associated
with Tyr177, we generated pools of interleukin-3 (IL-3)-depen-strate that Tyr177, and presumably Grb2 binding, contribute
to both myeloid and lymphoid leukemogenesis by BCR/ABL, dent murine Ba/F3 cells expressing either wild-type p210 BCR/
ABL (BCR/ABL-WT) or a Tyr177Phe substitution (Y177F) in thealthough Tyr177 is more important for the former. However,
the nature of the signaling pathway downstream of Tyr177 has BCR part of the fusion protein. For comparison, a BCR/ABL
construct with a mutation in its CRKL binding site (CRKL), aremained elusive. Because BCR/ABL can stimulate Ras through
other mechanisms, at least in hematopoietic cell lines, activated proline-rich region in the ABL part of the fusion protein (Senechal
et al., 1996), and a Grb2/Crkl binding site double mutantRas may not be the only or even the principal effector of Grb2
in BCR/ABL-expressing cells. Instead, Tyr177, acting via Grb2, (FCRKL), were also used to generate Ba/F3 cell pools. Pro-
longed growth of BCR/ABL-expressing Ba/F3 cells in the ab-may send another signal(s) required for myeloid transformation
and important for determining the latency of lymphoid leukemo- sence of IL-3 can lead to progressive changes in patterns of
signal transduction, possibly from the mutagenic effects of BCR/genesis.
Here we identify the scaffolding adaptor Gab2 as an essen- ABL kinase activity (Nieborowska-Skorska et al., 2000). We were
concerned that some of the discrepancies in the reported effectstial mediator of BCR/ABL transformation. Gab2, a member of the
family of PH-domain containing adaptor proteins that includes of BCR/ABL-Y177F (see Introduction) might be caused by such
secondary mutations. Therefore, to avoid this potential problemmammalian Gab1 (Holgado-Madruga et al., 1996) and Gab3
(Wolf et al., 2002) and Drosophila DOS (daughter of sevenless) and control for clonal variation, we studied polyclonal cell popu-
lations (pools) selected for G418 resistance rather than cytokine-(Herbst et al., 1996; Raabe et al., 1996), becomes tyrosine phos-
phorylated in response to a multiple cell stimuli (Gu et al., 1997, independence, and maintained these pools in the presence of
IL-3 and the ABL kinase inhibitor STI571 (Gleevec). Cell activa-1998, 2001; Lynch and Daly, 2002; Miyakawa et al., 2001; Ni-
shida et al., 1999; Wickrema et al., 1999; Zhao et al., 1999). tions were initiated by removal of STI571 and IL-3.
To ensure that each mutant had the expected phenotype,Reverse genetic and/or genetic analyses implicate Gab2 as a
positive (signal-enhancing) component of growth factor, cyto- we measured the interaction between Grb2 or Crkl and BCR/
ABL in the Y177F, CRKL, and FCRKL mutants by immuno-kine, and antigen receptor signal transduction (Gu et al., 1998,
2000, 2001; Liu et al., 2001; Lynch and Daly, 2002), although precipitation followed by immunoblotting (Figure 1A). As expected,
Grb2 did not coimmunoprecipitate with the BCR/ABL-Y177F andit may have a negative regulatory role in T cell receptor signaling
(Pratt et al., 2000; Yamasaki et al., 2001). We reported previously -FCRKL mutants, whereas Crkl failed to coprecipitate with BCR/
ABL-CRKL or -FCRKL mutants. We next explored the effectsthat Gab2 is constitutively tyrosine phosphorylated in BCR/ABL-
transformed cells (Gu et al., 1997, 1998). However, its mecha- of the Y177F mutation on total cellular tyrosine phosphorylation.
Although overall tyrosine phosphorylation was similar in BCR/nism of phosphorylation and role in BCR/ABL transformation
have remained unclear. ABL-WT- and mutant-expressing cells, cells expressing BCR/ABL-
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Figure 1. Grb2 binding site in BCR/ABL regulates tyrosine phosphorylation of Gab2
A–F: Ba/F3 cells expressing BCR/ABL-WT or the indicated BCR/ABL mutants were used. A: Lysates from 20  106 cells were subjected to immunoprecipitation
with anti-Grb2 or anti-CRKL antibodies, and coimmunoprecipitation of BCR/ABL was assessed by immunoblotting as indicated. The blots were reprobed
with anti-Grb2 or anti-CRKL antibodies, as indicated, to control for equal loading. B: The indicated cell lysates (from 0.25  106 cells) were subjected to
anti-phosphotyrosine immunoblotting. The blot was reprobed with anti-Abl and anti-p85-PI3K antibodies, as indicated. Note equal loading of protein (as
assessed by p85-PI3K blot) and comparable expression of each BCR/ABL protein. C: Anti-Gab2 immunoprecipitates were prepared from cell lysates as in
A, and successively immunoblotted with antibodies against phosphotyrosine, Abl, Gab2, Shp2, and p85-PI3K, as indicated. D–F: Lysates from 20  106 cells
were subjected to immunoprecipitations with antibodies against Abl (D), p85-PI3K (E), or Shp2 (F), followed by immunoblotting with the indicated antibodies.
For all panels, the migration positions of molecular mass markers (in kDa) are indicated.
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Y177F exhibited distinctly reduced tyrosine phosphorylation of
proteins with apparent molecular weights of 40, 72, 100, 120,
and 150 kDa. In CRKL mutant-expressing cells, there was
less of an effect on cellular phosphotyrosine proteins, although
proteins with apparent molecular weights of 30–40 kDa and a
160 kDa species showed consistent decreases (Figure 1B, top
panel). The pattern of phosphotyrosine-containing proteins in
BCR/ABL-FCRKL-expressing cells was the sum of the individ-
ual single mutants. Reprobing these immunoblots with anti-ABL
and anti-p85-PI3K antibodies confirmed that all of the cell lines
expressed comparable levels of BCR/ABL compared to these
internal controls (Figure 1B, middle and bottom panels).
The size and appearance of the 100 kDa phosphotyrosine
protein that exhibited decreased phosphorylation in BCR/ABL-
Y177F cells were reminiscent of the scaffolding adaptor Gab2.
Since Gab2 is phosphorylated in multiple BCR/ABL-WT trans-
formed cell lines, including BCR/ABL-transformed Ba/F3 cells
(Gu et al., 1997, 1998), we asked whether the 100 kDa species
was Gab2. Indeed, tyrosine phosphorylation of Gab2 was re-
duced markedly (70% as determined by scanning densitome-
try) in cells expressing BCR/ABL-Y177F or BCR-ABL-FCRKL,
but not in cells expressing BCR/ABL-CRKL (Figure 1C). Gab2
also coimmunoprecipitated with BCR/ABL-WT and BCR/ABL-
CRKL, but to a much lesser extent with BCR/ABL-Y177F (or
BCR/ABL-FCRKL) (Figure 1C and 1D). Taken together, these
results indicate that Tyr177 is required for binding of Gab2 to
BCR/ABL and for efficient BCR/ABL-evoked tyrosine phos- Figure 2. BCR/ABL-evoked tyrosine phosphorylation of Gab2 requires Grb2
phorylation of Gab2. Notably, some residual BCR/ABL-evoked A: Grb2 binds directly to Gab2. Gab2 immunoprecipitates (20  106 cells/
Gab2 tyrosine phosphorylation was observed even in the ab- sample) from randomly growing Ba/F3 cells () or cell pools expressing BCR/
ABL-WT or BCR/ABL-Y177F, as indicated, were resolved by SDS-PAGE andsence of Tyr177 (and in the absence of cytokines). Therefore,
transferred to a PVDF-membrane. Direct binding of GST or a GST-Grb2 fusionat least one additional pathway from BCR/ABL must be capable
protein was assessed by protein overlay assay. Note that Grb2 binds toof causing low levels of Gab2 phosphorylation.
Gab2 directly, specifically, and constitutively.
B: Ba/F3.BCR/ABL-WT cells were transfected with vectors that express Gab2-
Reduced binding of Gab2-associated signaling HA or a Gab2 mutant containing deletions of its Grb2 binding sites (Gab2-
HA.GRB2). Lysates from 20  106 cells were subjected to anti-HA immuno-proteins in cells transformed by BCR/ABL-Y177F
precipitations and tyrosine phosphorylated proteins (p-Tyr), or HA-taggedGab2 contains binding sites for the SH2 domains of the p85
Gab2 (HA), Abl, Shp2, and PI3K detected by immunoblotting, as indicated.
subunit of PI3K (p85-PI3K) and Shp2. Like Gab2, Shp2 (but For all panels, the migration positions of molecular mass markers (in kDa)
not p85-PI3K) is tyrosine phosphorylated constitutively in BCR/ are indicated.
ABL-transformed cells (Gu et al., 1997; Tauchi et al., 1994). In
cells transformed by BCR/ABL-WT or BCR/ABL-CRKL, p85-
PI3K and Shp2 were detected in anti-Gab2 (Figure 1C) and in
anti-ABL (Figure 1D) immune complexes. Likewise, Gab2 was Grb2 mediates the interaction of Gab2 with BCR/ABL. Ba/F3,
found in anti-p85-PI3K (Figure 1E) and anti-Shp2 (Figure 1F) Ba/F3.BCR/ABL-WT, and Ba/F3.BCR/ABL-Y177F cell lysates
immunoprecipitates. In contrast, Gab2/p85-PI3K and Gab2/ were subjected to immunoprecipitations with anti-Gab2 anti-
Shp2 association, as well as Shp2 tyrosine phosphorylation, bodies, and direct binding of Grb2 was assessed by a protein
were reduced dramatically in cells transformed by BCR/ABL- overlay assay. Notably, Gab2 bound to Grb2, and this interac-
Y177F, consistent with the substantially decreased Gab2 tyro- tion was independent of BCR/ABL-Y177 (Figure 2A).
sine phosphorylation in these cells (Figures 1D–1F). Thus, the Gab2 contains two proline-rich domains that can bind to
Y177F mutation causes a marked reduction in Gab2 binding to the Grb2 SH3 domains (Lock et al., 2000). To determine if the
BCR/ABL, decreased tyrosine phosphorylation of Gab2 and the Grb2 SH3 domain binding sites in Gab2 are required for the
Gab2-associated signaling protein, Shp2, and reduced binding tyrosine phosphorylation of Gab2, BCR/ABL-WT-expressing
of p85-PI3K to Gab2 and BCR/ABL. These findings indicate Ba/F3 cells were transfected transiently with a vector expressing
that Gab2 mediates, at least in part, interaction of Shp2 with HA-tagged wild-type Gab2 (Gab2-HA) or a Gab2 mutant lacking
BCR/ABL. Moreover, a significant amount of p85-PI3K, and by Grb2 SH3 domain binding sites (Gab2-HA.Grb2). Whereas
inference, PI3K (see below) must associate with BCR/ABL via Gab2-HA was robustly tyrosine phosphorylated in response to
BCR/ABL, BCR/ABL-evoked tyrosine phosphorylation of Gab2-Gab2.
HA.Grb2 was undetectable. The mutant Gab2 protein also
failed to bind to BCR/ABL, Shp2, and PI3K (Figure 2B). Thus,Gab2 is recruited to BCR/ABL via Grb2
Since Tyr177 of BCR is a Grb2 SH2 domain binding site (Pender- via its SH3 domain(s), Grb2 binds to Gab2 constitutively. The
Grb2/Gab2 complex is then recruited to BCR/ABL via bindinggast et al., 1993; Puil et al., 1994), and the Grb2 SH3 domains
bind Gab2 (Gu et al., 2000; Lock et al., 2000), we asked whether of the Grb2 SH2 domain to phosphorylated Tyr177 of BCR/ABL.
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Figure 3. Effect of Tyr177 mutation on BCR/ABL-
evoked biochemical and biological events
A: Tyr177 regulates PI3K activation by BCR/ABL.
Lysates (25  106 cells) from Ba/F3 cells or Ba/F3
cells expressing BCR/ABL-WT or BCR/ABL-Y177F,
as indicated, were immunoprecipitated with the
indicated antibodies, and the resultant immune
complexes were subjected to in vitro PI3K kinase
assays, followed by thin-layer chromatography
and autoradiography. The position of migration
of phosphatidylinositol-3 phosphate (as deter-
mined by iodine staining of nonradioactive stan-
dards) is indicated. PIP3 production, as quanti-
fied by scanning densitometry (see Experimental
Procedures), was decreased 60%–70% in anti-
phosphotyrosine immunoprecipitates, 70%–80%
in anti-Gab2 immunoprecipitates, and 65%–75%
in anti-Abl immunoprecipitates (corresponding
to 2–4 experiments with each antibody).
B: Tyr177 regulates Akt and Erk activation. Lysates
from the indicated cells (0.25  106) were sub-
jected to immunoblotting with phosphospecific
antibodies to Akt (p-Akt), Gsk-3 (p-Gsk-3), and
Erk proteins (p-Erk). To control for loading, the
blots were stripped and reprobed with antibod-
ies against total Akt (AKT), Gsk-3 (GSK-3), or
Erk1 and Erk2 (ERK1/2).
C: Tyr177 regulates BCR/ABL-evoked Ba/F3 cell
proliferation. Proliferation of the indicated Ba/F3
cell lines was monitored in the absence (top) or
the presence (bottom) of IL-3 and STI571. Ba/
F3.BCR/ABL-WT,H17009 Ba/F3.BCR/ABL-Y177F. Data
are expressed as fold increase in cell number
(determined by Coulter counting) over the time
of the assay. Shown is one of three representative
experiments. *Significant differences (p  0.02)
were observed between Ba/F3.BCR/ABL-WT and
Ba/F3.BCR/ABL-Y177F cells.
D: Optimal BCR/ABL-evoked haplotaxis requires
Tyr177. Ba/F3 cells expressing BCR/ABL-WT or
BCR/ABL-Y177F were used in transwell migration
assays. The number of viable cells in the lower
chamber was determined after 3 hr by trypan
blue exclusion. Error bars indicate the standard
error of the mean (n3).
Upon recruitment, Gab2 becomes tyrosine phosphorylated and cells transformed by BCR/ABL-Y177F, PI3K activity associated
with anti-phosphotyrosine, anti-ABL, or anti-Gab2 immunerecruits additional signal relay molecules, such as Shp2 and
p85-PI3K. complexes was reduced by 60%–80% (see Figure 3A legend).
These results show that Tyr177 is involved in the regulation of
PI3K and implicate Gab2 in regulating this activity.Tyr177 of BCR/ABL regulates multiple downstream
We next asked if Y177 regulates the activation of PI3K ef-signaling pathways
fectors. Indeed, the serine phosphorylation of Akt and Gsk-3PI3K is known to be activated by BCR/ABL, and is required for
was reduced in cells expressing BCR/ABL-Y177F (Figure 3B;BCR/ABL transformation of hematopoietic cells (Skorski et al.,
top and middle panels). Erk 1 and Erk2 activation were also1995). The reduced binding of p85-PI3K to Gab2 and BCR/ABL
diminished in these cells (Figure 3B, bottom panels). Thus,in BCR/ABL-Y177F-expressing cells suggested that Tyr177
Tyr177-derived signals contribute substantially to the regulationmight be involved in the regulation of PI3K activity. Therefore,
of multiple downstream signaling pathways known to be criticalwe measured the PI3K activity associated with anti-phosphoty-
for BCR/ABL transformation.rosine, anti-Gab2, and anti-ABL immune complexes (Figure 3A).
As reported previously (Sattler et al., 1996), PI3K activity in
phosphotyrosine immunoprecipitations was increased in cells Tyr177 in BCR/ABL regulates proliferation
and migrationtransformed by BCR/ABL-WT compared to untransformed cells.
Significant PI3K activity also was detected in anti-Gab2 and Previous studies of the effects of BCR/ABL Y177F on hemato-
poietic cells have been somewhat contradictory (see Introduc-anti-ABL immune complexes in BCR/ABL-WT cells. However, in
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tion and Discussion). At least some of these discrepancies may since their ability to be transformed by the TEL/JAK2 oncogene
was reduced only slightly (by at most 2-fold; data not shown).have been due to different protocols used to generate BCR/
ABL-expressing hematopoietic cell lines. As indicated above, Overall, our data indicate that Gab2 is required for transforma-
tion of murine bone marrow myeloid progenitors by BCR/ABLwe made a special effort to limit the exposure of our cell pools
to BCR/ABL kinase activity, thereby minimizing potentially mu- in a colony outgrowth assay, and suggest that at least some of
the transforming defects associated with the Y177F mutant aretagenic effects of BCR/ABL. Using this protocol, we compared
the effects of BCR/ABL-WT and BCR/ABL-Y177F on several due to failure to transmit appropriate signals through Gab2.
Since Gab2 (/) myeloid cells cannot be stably trans-different biological responses of Ba/F3 cells. Consistent with
previous results (Cortez et al., 1995), both of these proteins formed by BCR/ABL, extensive biochemical studies of the ef-
fects of BCR/ABL in these cells were not possible. Nevertheless,induced factor-independent growth of Ba/F3 cells. However,
Ba/F3 cell proliferation in the absence of added cytokines was by making use of retrovirus that coexpresses BCR/ABL-WT and
green fluorescence protein (GFP), we were able to infect primaryreduced in cells expressing BCR/ABL-Y177F, compared to
BCR/ABL-WT (Figure 3C, top panel). Addition of IL-3 restored myeloid cells from WT and Gab2 (/) bone marrow and re-
cover enough transduced cells for limited analyses (see Experi-growth of the BCR/ABL-Y177F mutant-expressing cell line to
levels comparable to that found in BCR/ABL-WT cells (Figure mental Procedures). Remarkably, Akt and Erk activation were
substantially reduced in BCR/ABL-transduced Gab2 (/) my-3C, bottom panel), indicating that BCR/ABL-Y177F cells do not
have a defect in proliferation per se, but only in BCR/ABL- eloid cells (Figure 4C); notably, these defects are qualitatively
similar to those observed in BCR/ABL Y177F-expressing Ba/evoked proliferation. BCR/ABL-WT-transformed Ba/F3 cells
demonstrate a significant level of spontaneous migration, as F3 cells (compared to BCR/ABL-WT.Ba/F3) and therefore sup-
port the notion that Gab2 is a key transducer of signal(s) frommeasured in a transwell migration assay (Salgia et al., 1999).
BCR/ABL-Y177F also evoked lower levels of spontaneous mi- Tyr177.
gration than BCR/ABL-WT (Figure 3D) and, as in the proliferation
experiments, the addition of IL-3 rescued the BCR/ABL-Y177F Gab2 determines the severity of lymphoid
transformation by BCR/ABLmigration defect. Analogous results were obtained in studies
in which BCR/ABL-WT or BCR/ABL-Y177F was expressed in In the murine bone marrow transduction/transplantation model,
BCR/ABL-Y177F exhibits a relative defect in lymphoid leukemo-32Dcl3 cells (another IL-3 dependent hematopoietic cell line;
data not shown). Thus, signals from Tyr177 contribute to both genic ability (in contrast to its more profound defect in myeloid
leukemogenesis; see Introduction). Therefore, we assessed theBCR/ABL-evoked proliferation and migration of hematopoietic
cell lines. susceptibility of Gab2 (/) B lymphoid cells to transformation
by BCR/ABL. Bone marrow cells from Gab2 (/) and Gab2
(/) mice were transduced with BCR/ABL-WT retrovirusesGab2 is required for transformation of primary
murine myeloid cells by BCR/ABL and cultured under conditions that favor outgrowth of trans-
formed B lymphoid cells (Whitlock-Witte cultures [McLaughlinThe above studies suggest that Gab2-associated signals may
be critical for BCR/ABL transformation. Therefore, we compared et al., 1987]; see Experimental Procedures). Unlike Gab2 (/)
myeloid cells, BCR/ABL-transformed Gab2 (/) B lymphoidthe ability of BCR/ABL to transform primary myeloid cells from
bone marrow of wild-type Gab2 (/) and Gab2 (/) mice. cells were observed. These cells had the same surface pheno-
type (B220/CD24/BP-1) as BCR/ABL-transformed Gab2Importantly, Gab2 (/) mice have normal steady state hemato-
poiesis and are otherwise healthy, although their allergic re- (/) B lymphoblasts (data not shown). However, when similar
numbers of transduced Gab2 (/) and Gab2 (/) bone mar-sponse is defective (Gu et al., 2001). Normal myeloid progenitors
require cytokines to form colonies in methylcellulose. Consistent row cells were plated, it took significantly longer for the latter
to reach confluence (Figure 5A). Transduction efficiency of Gab2with previous work (Gishizky and Witte, 1992), BCR/ABL-WT,
introduced by retroviral transduction, transformed a significant (/) and Gab2 (/) bone marrow was equivalent by determi-
nation of proviral copy numbers by Southern blot, and compara-number of progenitors from Gab2 (/) mice, leading to cyto-
kine-independent myeloid colonies (mainly CFU-GM, but a few ble numbers of pre- and pro-B cells from wild-type and mutant
bone marrow were GFP positive (data not shown). Thus, Gab2CFU-M and CFU-GEMM). However, BCR/ABL-WT was com-
pletely unable to transform bone marrow cells from Gab2 (/) (/) lymphoid cells have a cell autonomous defect in the estab-
lishment and/or maintenance of lymphoid transformation. Directmice (Figure 4A). Transduction of bone marrow cells from mice
of either genotype with the parental retrovirus did not cause evidence for the latter was provided by measuring the biological
properties of pools of BCR/ABL-transformed Gab2 (/) andcytokine-independent myeloid colony growth. Notably, in the
presence of IL-3, transduced bone marrow cells from Gab2 Gab2(/) B lymphoblasts. BCR/ABL-transformed Gab2 (/)
cells showed a substantial defect in cell proliferation (Figure(/) and Gab2 (/) mice gave rise to comparable numbers
of myeloid colonies, confirming that the bone marrow CFU-C 5B), as well as in spontaneous (i.e., haplotaxis) and chemokine-
induced migration (Figure 5C). Remarkably, BCR/ABL-evokedcontent of Gab2 (/) mice is normal and demonstrating that
BCR/ABL is not toxic to Gab2 (/) progenitors. Moreover, Akt and Erk activation also were defective in transformed Gab2
(/), compared to Gab2 (/), B lymphoblasts (Figure 5D).experiments using a green fluorescent protein (GFP)-expressing
retrovirus demonstrated that Gab2 (/) and Gab2 (/) bone To gain further insight into the reason for the defective prolif-
eration of BCR/ABL transformed Gab2 (/) B lymphoblasts,marrow cells had comparable susceptibility to retroviral trans-
duction (Figure 4B). Compared to BCR/ABL-WT, BCR/ABL- we performed cell cycle analysis. Although Gab2 deficiency did
not affect the distribution of cells in G1, S, and G2/M, thereY177F was only partially defective at inducing colony outgrowth
of Gab2 (/) myeloid cells (Figure 4A). Importantly, Gab2 (/) was a marked increase (5-fold) in the percentage of cells
with sub-G1 DNA content (Figures 6A and 6B). Apoptosis wasmyeloid cells are not completely refractory to transformation,
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Figure 4. Gab2 is required for BCR/ABL-evoked
myeloid colony outgrowth
A: Bone marrow cells from Gab2 (/) and lit-
termate Gab2 (/) mice were transduced with
retroviruses expressing BCR/ABL-WT (MSCV-
p210), BCR/ABL-Y177F (MSCV-p210Y177F), or the
parental control virus (MSCV-vector). The aver-
age number of colonies (from triplicate platings)
was determined in the absence (black columns)
or presence (gray columns) of 100 pg/ml murine
IL-3. Shown is a representative experiment from
four independent assays that yielded compara-
ble results. In these experiments, no colonies
were generated from Gab2 (/) bone marrow
cells transduced with BCR/ABL-WT (total of 106
bone marrow cells transduced in the four experi-
ments). Parallel experiments yielded a total of
approximately 300 colonies following transduc-
tion of Gab2 (/) bone marrow cells.
B: Bone marrow cells from Gab2 (/) and lit-
termate wild-type (WT) mice were transduced
with a retrovirus expressing the EGFP cDNA
and analyzed by flow cytometry. Note that
Gab2 (/) (15%) and Gab2 (/) (13%) cells
are comparably susceptible to retroviral trans-
duction.
C: BCR/ABL-transduced myeloid cells were iso-
lated by FACS, and Akt and Erk activation were
assessed as described in Experimental Proce-
dures.
confirmed by the presence of characteristic DNA laddering in defective BCR/ABL-evoked Erk and Akt activation. To gain in-
sight into which of these pathways might contribute to the in-the Gab2 (/) cells (data not shown). These data indicate that
inability of BCR/ABL to prevent apoptosis probably accounts creased apoptosis in the absence of Gab2, we treated BCR/
ABL-transformed Gab2 (/) B lymphoblasts with inhibitors offor the decreased proliferation of Gab2 (/) B lymphoblasts.
Our biochemical analyses indicate that Gab2 (/) cells exhibit these signaling pathways. The PI3K inhibitor LY294002 and the
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Figure 5. Gab2 contributes to, but is not required for, lymphoid transformation
A: The indicated number of bone marrow cells from Gab2 (/) and Gab2 (/) mice were transduced with BCR/ABL-WT retrovirus and cultured under
conditions that favor outgrowth of transformed B lymphoblasts (Whitlock-Witte cultures; see Experimental Procedures). The time required for the culture to
reach confluence (corresponding to 106 B lymphoblasts) is shown. Each bar represents three independent wells seeded with the indicated number of
bone marrow cells. Note that BCR/ABL can transform Gab2 (/) B cells, but with decreased efficiency. When lower numbers of cells were plated (1–3 
103/well), BCR/ABL-evoked transformation was observed in some Gab2 (/) wells, but not in Gab2 (/) wells. Shown is a representative experiment
from three independent assays that yielded comparable results.
B: Proliferation of BCR/ABL-transformed Gab2 (/) and Gab2 (/) B lymphoblasts, as measured by [3 H]-thymidine incorporation.
C: BCR/ABL-transformed Gab2 (/) and Gab2 (/) B lymphoblasts were subjected to transwell migration assays in the presence or absence of the
chemokine SDF-1.
D: Akt and Erk activation in BCR/ABL-transformed Gab2 (/) and Gab2 (/) B lymphoblasts was measured by immunoblotting with the indicated
phospho-specific antibodies, followed by reprobing for levels of the respective proteins to control for loading.
MEK inhibitor U0126 markedly increased apoptosis of these nals in BCR/ABL transformed B lymphoblasts, and that de-
creases in these signaling pathways contribute to the increasedcells (Figure 6C). Similar results were obtained with the MEK
inhibitor PD98059 (data not shown). These data suggest that apoptosis and consequently decreased proliferation observed
in the absence of Gab2.both the PI3K/Akt and Ras/Erk pathways transmit survival sig-
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Figure 6. Lack of Gab2 results in increased apoptosis of BCR/ABL-trans-
formed B lymphoblasts
A and B: Flow cytometric profiles of propidium-iodide-stained BCR/ABL-
transformed Gab2 (/) (A) and Gab2 (/) (B) B lymphoblasts. Note the
similar cell cycle distribution, but the marked increase in apoptotic cells
(indicated by sub-G1 DNA content) in Gab2 (/) cells. Figure 7. Model for the role of Gab2 in BCR/ABL transformation
C: Shown are the percentages of cells in the indicated cell cycle stages,
Autophosphorylation of BCR/ABL generates phosphorylated Tyr177, whichas well as the percentage of viable cells (as determined by excluding cells
binds to the SH2 domain of Grb2. This leads to recruitment and tyrosinewith sub-G1 DNA content) in BCR/ABL-transformed Gab2 (/) and Gab2
phosphorylation of Gab2, which binds constitutively to the Grb2 SH3 do-(/) B lymphoblasts, and BCR/ABL-transformed Gab2 (/) cells treated
main. Tyrosine phosphorylated Gab2 binds to signal relay molecules, includ-with the indicated inhibitors.
ing PI3K, which is required for Akt activation, and Shp2, which may be
important for Erk activation. Akt and Erk both send antiapoptotic signals,
and may also contribute to BCR/ABL-evoked migration. Together, these
and perhaps other Gab2-generated signals are required for myeloid trans-
formation and contribute to lymphoid transformation, and ultimately leuke-Discussion
mia. The thicker lines indicate that the PI3K/Akt pathway may be more
important for promoting survival. Multiple arrows indicate the existence ofIncreasing evidence suggests that the BCR component of BCR/
several intervening steps in a pathway, whereas dashed lines represent
ABL fusion proteins determines the aggressiveness and lineage potential connections that have not yet been demonstrated.
of BCR/ABL-induced leukemia. The BCR autophosphorylation
site Tyr177, a Grb2 binding site, is required for transformation
of fibroblasts (Pendergast et al., 1993) and for efficient induction
of CML-like myeloproliferative disease by BCR/ABL (Million and site for the Grb2 SH2 domain (Pendergast et al., 1993; Puil et
Van Etten, 2000; Zhang et al., 2001; He et al., 2002). Tyr177 al., 1994), and the Grb2 SH3 domains associate constitutively
also plays a significant, although less profound, role in lymphoid with proline-rich motifs in Gab2 (Gu et al., 1998, 2000; Lock et
leukemogenesis (Million and Van Etten, 2000; Zhang et al., 2001; al., 2000; Figure 2A), these findings suggested that Gab2 is
He et al., 2002). Whether Grb2 is, indeed, the key Tyr177 binding recruited to, and subsequently phosphorylated by, BCR/ABL
protein, as well as the nature of the signaling pathways activated (or a BCR/ABL-associated kinase) via a Grb2/Gab2 complex
(Figure 7). Consistent with this model, a Gab2 mutant lackingby direct binding of Grb2 to BCR/ABL, has been controversial
(see Introduction). Here, using a combined biochemical and Grb2 binding sites is defective in BCR/ABL association, tyrosine
phosphorylation, and binding to Shp2 and PI3K (Figure 2B).genetic approach, we have identified the scaffolding adaptor
protein Gab2, which binds to Grb2, as a critical mediator of the Although a previous study suggested that Shp2 associates di-
rectly with BCR/ABL (Tauchi et al., 1994), our results argue thatTyr177 signal.
We showed previously that, whereas Gab2 becomes tyro- Shp2 tyrosine phosphorylation and BCR/ABL association are
mediated mainly via Gab2.sine phosphorylated in response to a wide variety of cell stimuli,
including several hematopoietic cell growth factors and cyto- Recruitment via Grb2 is likely to be a general mechanism
for activating Dos/Gab family members. In response to c cyto-kines, it is constitutively tyrosine phosphorylated and associated
with signal relay molecules in multiple BCR/ABL-transformed kines, and possibly cytokines that signal via the IL-2 receptor
 chain, Gab2 tyrosine phosphorylation is mediated primarilycell lines (Gu et al., 1997, 1998). The results herein show that
Gab2 also associates with BCR/ABL, and efficient Gab2 tyrosine by a Shc-Grb2-Gab2 complex (Gu et al., 2000). The Gab2 rela-
tive Gab1 is also recruited to some growth factor receptors viaphosphorylation and BCR/ABL association require Tyr177
phosphorylation (Figures 1C and 1D). Since Tyr177 is a binding Grb2 (Lock et al., 2000; Schaeper et al., 2000), and a recent
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study indicates that Gab1 binds to polyoma middle T antigen in experiments such as those in Figure 5A, Gab2 (/) cells
can yield lymphoid cell transformation, whereas no transforma-through a Shc/Grb2 complex (Ong et al., 2001). Since Dos/
Gab proteins activate multiple downstream signaling pathways, tion was observed using Gab2 (/) bone marrow despite equal
levels of transduction and prolonged culture (data not shown).signals emanating from Dos/Gab family scaffolds may be as
important for Grb2 function as is its ability to recruit Sos to Furthermore, Gab2 (/) B lymphoblasts have defective haplo-
taxis and chemotaxis (Figure 5C), which also should affect leu-activated receptors. Transforming proteins such as BCR/ABL
(and perhaps middle T antigen and others) can subvert this kemic phenotype.
We cannot conclude that Gab2 is the only essential down-normal Grb2/Gab2 (or Shc/Grb2/Gab2) signaling pathway. Con-
ceivably, Gab2 plays an important role in the pathogenesis of stream mediator of the Tyr177 signal; other Grb2 binding pro-
teins may be recruited via Y177 and might be required for BCR/other types of neoplasms as well; notably, a high percentage
of breast cancer cell lines and tumors overexpress Gab2 (Daly ABL transformation. The role of such proteins in BCR/ABL trans-
formation, and whether their recruitment is dependent or inde-et al., 2002).
Our work provides compelling evidence that Gab2 is an pendent of Gab2, remains to be determined by genetic analysis.
Nevertheless, we favor the notion that Gab2 is the major, if notessential mediator of leukemogenic signals emanating from
Tyr177. Cell proliferation and spontaneous migration are im- the only, transforming signal from Tyr177. Whereas Gab2 (/)
myeloid progenitors are refractory to BCR/ABL transformation,paired significantly in BCR/ABL-Y177F Ba/F3 (and 32Dcl3) cells
compared to BCR/ABL-WT cells (Figure 3). Gab2 (/) and the transforming ability of BCR/ABL-Y177F (for wild-type my-
eloid cells) is only reduced, not absent. These findings parallelGab2 (/) bone marrow cells yield similar numbers of myeloid
colonies in the presence of cytokines (Figure 4A), but whereas the marked reduction (but not absence) of Gab2 tyrosine phos-
phorylation, and the decreased, but not absent, PI3K, Akt, andBCR/ABL-WT gives rise to cytokine-independent myeloid colo-
nies when introduced into Gab2 (/) progenitors (Gishizky and Erk activation in BCR/ABL-Y177F-expressing cells, suggesting
that a small amount of Gab2 can be tyrosine phosphorylatedWitte, 1992; Figure 4A), Gab2 (/) progenitors are refractory
to BCR/ABL transformation. Several studies indicate a good by alternative means in the absence of Tyr177. Shc is tyrosine
phosphorylated in BCR/ABL-expressing cells (Goga et al.,correlation between the factor-independent myeloid colony
assay and myeloid leukemogenesis by BCR/ABL mutants 1995); conceivably, the residual Gab2 phosphorylation in BCR/
ABL-Y177F cells could be generated via a Shc/Grb2/Gab2 com-(Gross and Ren, 2000; Nieborowska-Skorska et al., 1999; Skor-
ski et al., 1997). Myeloid leukemogenesis studies (which require plex, as in c cytokine signaling (Gu et al., 2000). The striking
similarity between the effect of Tyr177 mutation on BCR/ABLcrossing the Gab2 mutation onto Balb/c background) are in
progress in our laboratories. leukemogenesis in vivo and the consequences of Gab2-defi-
ciency on myeloid and lymphoid transformation ex vivo alsoGab2 may be particularly important for myeloid transforma-
tion by BCR/ABL, compared to other oncogenic tyrosine kinase argue that Gab2 is the physiologically relevant target of Tyr177.
Additional support for this conclusion is provided by the compa-fusions. Like BCR/ABL, TEL/JAK2 evokes Gab2 tyrosine phos-
phorylation and association with Shp2 and PI3K (Nguyen et al., rable increase in apoptosis in Gab2 (/) B cells transformed by
BCR/ABL and BCR/ABL-transformed Gab2 (/) cells treated2001) (J. Franstve, H.G., D. Sternberg, M.G.M., B.G.N., and
D.G. Gilliland, unpublished data). However, in contrast to BCR/ with inhibitors of two pathways (PI3K/Akt and Ras/Erk, respec-
tively) affected by Gab2 deficiency (Figure 6).ABL, TEL/JAK2 evokes factor-independent myeloid colonies
from Gab2 (/) bone marrow cells (data not shown; J. Frans- Two pathway(s) downstream of Gab2, the PI3K/Akt and
Ras/Erk pathways, appear to be critical, at least for lymphoidtve, H.G., D. Sternberg, M.G.M., B.G.N., and D.G. Gilliland,
unpublished data). Interestingly, BCR/ABL and TEL/JAK2 also transformation (Figures 5 and 6). PI3K activity is required for
BCR/ABL transformation (Skorski et al., 1995), but the mecha-have contrasting requirements for Stat5: Stat5 is dispensable
for BCR/ABL transformation (Sexl et al., 2000), but essential for nism of PI3K activation by BCR/ABL has been controversial.
BCR/ABL has a consensus binding site (Y-X-X-M) for p85-PI3K,leukemogenesis by TEL/JAK2 (Schwaller et al., 2000). Thus,
different oncogenic-tyrosine kinase fusion proteins may have but mutation of this site does not abrogate PI3K activation or
association with BCR/ABL (Jain et al., 1996). Instead, Skorskidistinct transformation requirements, with obvious therapeutic
implications. et al. reported that activation of PI3K by BCR/ABL requires the
ABL SH2 domain. These workers found no effect of Tyr177Gab2 also is an important mediator of lymphoid transforma-
tion signals from Tyr177. Remarkably, just as lymphoid leuke- mutation on BCR/ABL-evoked PI3K activity (Skorski et al.,
1997). In contrast, Roumiantsev et al. found that the SH2 domainmogenesis is affected less severely than myeloid leukemogene-
sis by Y177F mutation (Million and Van Etten, 2000; Zhang of BCR/ABL was dispensable for PI3K activation (Roumiantsev
et al., 2001). The reason for this discrepancy is not clear. How-et al., 2001; He et al., 2002), the defect in BCR/ABL-evoked
transformation of Gab2 (/) B lymphoblasts is milder than ever, our results show that coimmunoprecipitation of p85-PI3K
with BCR/ABL-Y177F is reduced markedly, at least in part be-the (absolute) defect in myeloid transformation by BCR/ABL.
Nevertheless, multiple aspects of lymphoid leukemogenesis cause of failure of BCR/ABL-Y177F to bind to Gab2 (Figure 1).
Moreover, PI3K activity is reduced in anti-phosphotyrosine, anti-may be altered in the absence of Gab2. BCR/ABL-transformed
B lymphoblasts clearly have a cell autonomous proliferation ABL, and anti-Gab2 immunoprecipitates in cells expressing
BCR/ABL-Y177F, and at least two critical targets of the PI3Kdefect (Figure 5B), most likely due to increased apoptosis (Fig-
ure 6); obviously, such a defect could contribute to the increased pathway, Akt and Gsk-3, exhibit decreased activation in these
cells (Figure 3). These data suggest that Tyr177 is criticallylatency of lymphoid leukemias evoked by BCR/ABL-Y177F.
There probably is an independent defect in establishment of involved in the regulation of PI3K binding and biological activity
and implicate Gab2 in BCR/ABL activation of the PI3K/Akt path-lymphoid transformation in Gab2 (/) mice. If lower numbers
of BCR/ABL retrovirus-transduced bone marrow cells are plated way. Consistent with this notion, BCR/ABL-evoked Akt activa-
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Gab2 (/) and Gab2 (/) B lymphoblasts were maintained in RPMI plustion is diminished in primary myeloid (Figure 4) and lymphoid
20% FCS, antibiotics, and 50 	M 2-mercaptoethanol (2-ME).(Figure 5) cells from Gab2 (/) mice. Notably, Gab2 is also
essential for PI3K activation in normal signaling pathways, such
Expression constructsas signaling from the high affinity IgE receptor and the IL-3
BCR/ABL-WT, BCR/ABL-Y177F, BCR-ABL-CRKL, and BCR/ABL-FCRKL
receptor in mast cells and factor dependent hematopoietic cell cDNAs (kindly provided by Dr. Brian Druker, Oregon Health Sciences Center)
lines (Gu et al., 2000, 2001). Since PI3K activation is only partially were subcloned into the EcoRI site of the pcDNA3 expression vector (Clon-
defective in BCR/ABL-Y177F cells, other BCR/ABL-evoked tech Laboratories, Palo Alto, CA), and used for transfection by electropora-
tion into Ba/F3 cells. pEBB expression vectors containing HA-tagged murinepathways to PI3K activation must exist. Also, Gab2 may not be
Gab2 cDNA (Gab2-HA) (Gu et al., 1998) or Gab2 cDNA with mutationsthe only route from Tyr177 to the PI3K pathway; preliminary
in the Grb2 binding sites (Gab2-HA.GRB2, kindly provided by Drs. Lisastudies indicate that Cbl tyrosine phosphorylation is also im-
Lock and Morag Park, McGill University, Canada) were used for electropor-paired by the Y177F mutation (M.S. and J.D.G., unpublished
ation into Ba/F3.BCR/ABL-WT cells. There are two potential Grb2 binding
data), and Cbl interacts with PI3K in BCR/ABL-transformed cells sites on Gab2 (Lock et al., 2000). In Gab2-HA.GRB2, one of the sites
(Sattler et al., 1996). Nevertheless, our data suggest that the (S344AIAPPPRPP353) was deleted, and the other was mutated (P498PPVNR503
fraction of PI3K activation mediated via Gab2 is of key patho- to P498APVNA503).
physiological importance. Decreased PI3K activation is likely
Bone marrow transduction and transformation assaysnot the sole cause of impaired transformation by BCR/ABL-
High-titer, helper virus-free retroviral stocks of MSCVneo p210 (BCR/ABL),Y177F. Impaired Erk activation (Figure 5B), which may reflect
MSCVneo p210 (BCR/ABL)-Y177F, and MSCVneo were prepared by tran-reduced recruitment of Grb2/Sos and/or reduced signaling
sient transfection of 293T cells using the kat ecotropic packaging system,
through Gab2 via Shp2-dependent or independent pathways,
as described previously (Million and Van Etten, 2000). All viral stocks had
also contributes (Figure 6C). titers of 3 to 5  106 neomycin-resistant colony-forming units/ml in NIH 3T3
Overall, our results strongly support the concept that the cells and gave rise to equivalent proviral copy numbers in transduced NIH3T3
profound defects in transformation associated with the Y177F or primary bone marrow cells, as determined by Southern blotting. Gab2
(/) and littermate Gab2 (/) mice (129Sv X C57Bl6/J) were describedmutation of BCR/ABL are due, in part or in total, to the failure
previously (Gu et al., 2001).of this mutant to recruit Grb2/Gab2 complex(es), and the subse-
For ex vivo colony formation assays, bone marrow cells harvested fromquent reduction in the ability of BCR/ABL to activate the PI3K/
6–10 week old mice were prestimulated at 37
C in IMDM with 15% (v/v)
Akt, Ras/Erk, and perhaps other, as yet undefined, pathways. heat-inactivated FCS, 5% (v/v) WEHI-3B conditioned medium, 1 	g/ml ci-
These defects would significantly impair viability and motility profloxacin, and murine IL-3 (6 ng/ml, Upstate Biotechnology), IL-6 (10 ng/ml,
signals from BCR/ABL (Figures 5 and 6), consistent with the R&D Systems), and SCF (50 ng/ml, R&D Systems). The next day, cells were
ex vivo and in vivo effects of BCR/ABL-Y177F. An additional transferred into 6-well plates, exposed to viral supernatants in prestimulation
medium in the presence of 10 mM HEPES (pH 7.5) and 2 	g/ml polybrene,implication of our results is that key transforming signals from
and centrifuged at 2500 rpm for 90 min at 30
C. After adsorption for 4 hrBCR/ABL are mediated by a pathway that is dispensable for
at 37
C, the medium was changed with fresh prestimulation medium. At 48normal, basal hematopoiesis. The development of the ABL in-
hr, a second round of transduction and cosedimentation was performed.
hibitor STI571 has had a dramatic effect on the therapy of CML After a 3 hr adsorption period, the cells were washed once with IMDM,
(BCR/ABL disease) (Mauro et al., 2002). However, it is clear that counted, and plated in triplicate in MethoCult M3234 medium (StemCell
resistance to STI571 will limit its therapeutic efficacy (Barthe et Technologies, Vancouver) at 8  104 cells/35 mm dish in the presence or
absence of murine IL-3 (100 pg/ml) at 37
C, 5% CO2, as indicated. Coloniesal., 2001; Gorre et al., 2001; Hochhaus et al., 2001). Identifying
were scored at day 12. In some experiments, bone marrow cells were trans-targets for other signal transduction inhibitors that are comple-
duced with MSCV-GFP, and the efficiency of transduction of Gab2 (/) andmentary to STI571 without adding toxicity to normal blood cells
Gab2 (/) cells was determined by flow cytometry for the GFP fluorophore.is critical; Gab2-dependent pathways provide a source of such
For primary B lymphoid transformation assays (McLaughlin et al., 1987),
targets. Intriguingly, pharmacological inhibition of two of these bone marrow cells were treated with NH4Cl solution to lyse erythrocytes,
pathways, the PI3K and Erk pathways, evokes apoptosis of and then transduced by cosedimentation with p210 BCR/ABL-expressing
BCR/ABL-transformed B lymphoblasts (Figure 6). Inhibitors of retroviruses for 90 min at 30
. After adsorption for 3 hr at 37
C, cells were
these pathways, most likely in combination with STI571, may plated (1  106 total cells/well) into 24-well plates at different densities
in the absence (only at the highest density) or presence of feeder cellsbe useful for treatment of CML blast crisis. Finally, it will be
(untransduced bone marrow cells) in 1 ml of Whitlock/Witte culture mediumimportant to define the role of Gab2 and Gab2-dependent path-
(RPMI 1640, 20% fetal calf serum, 1 	g/ml ciprofloxacin, and 50 	M 2-ways in transformation by other tyrosine kinase oncogenes.
mercaptoethanol). Cultures were scored as transformed when the number
of nonadherent cells exceeded 106 per ml of culture medium. Similar resultsExperimental procedures
were obtained when feeder cells were supplied by Gab2 (/) or Gab2
(/) bone marrow cells. Transformed cells were expanded from these wellsCell culture
and maintained as described above.The murine hematopoietic line Ba/F3 was grown in RPMI 1640 with 10%
(v/v) fetal calf serum (FCS) and 10% (v/v) WEHI-3B conditioned medium (as
Immunoprecipitation and immunoblottinga source of murine IL-3), plus antibiotics (Penicillin/Streptomycin). Pools of
Cells were lysed in a buffer containing Tris-HCl (50 mM, pH 8.0), NaCl (150Ba/F3 cell lines transfected to express BCR/ABL-WT, BCR/ABL-Y177F,
mM), NP40 (1% v/v), deoxycholic acid (0.5% w/v), sodium dodecyl sulfateBCR/ABL-CRKL, and BCR/ABL-FCRKL (all in the backbone of p210 BCR/
(0.1% w/v), NaF (100 mM), and glycerol (10% v/v). ImmunoprecipitationABL) were selected for G418 resistance (2 mg/ml). The G418-resistant cells
and immunoblotting using a chemiluminescence technique were performedwere maintained in Ba/F3 culture medium in the presence of the ABL kinase
using standard methods. Tyrosine phosphorylated proteins were detectedinhibitor STI571 (1 	g/ml) to limit the long-term mutagenic effects of BCR/
using the monoclonal antibody 4G10 (kindly provided by Dr. Brian Druker,ABL. For biochemical experiments, these polyclonal cell lines were grown
Oregon Health Science University, Portland, OR). Polyclonal rabbit antiserafor 18 hr in the absence of STI571 and WEHI-3B conditioned medium. The
against Gab2, Cbl, and Shp2 (Santa Cruz Biotech, Santa Cruz) and mono-number of viable cells was determined by trypan blue exclusion, or total cell
clonal anti-HA (12CA5) and ABL (3F12) antibodies were used for immunoblot-number was determined using a Coulter particle counter (Coulter Counter
Z2). Following their generation as described below, BCR/ABL-transformed ting and/or immunoprecipitation. In some studies, phospho-specific antibod-
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ies reactive with Ser473 of Akt or Ser9 of Gsk-3 (Cell Signaling Technology, Award, and M.G.M. is the recipient of a Fellowship, from the Leukemia and
Lymphoma Society. H.G. was the recipient of the Anna D. Barker FellowshipBeverly, MA) or Tyr204 of Erk1 and Erk2 (Santa Cruz Biotech) were used.
For biochemical analysis of primary myeloid cells, bone marrow was from the American Association for Cancer Research.
transduced with MSCV-p210 BCR/ABL-IRES-GFP, and transduced cells
were purified by FACS for the GFP fluorophore. Sorted cells were cultured
overnight in a cytokine cocktail (mIL-3, mIL-6, and mSCF), and an equal
number of live Gab2 (/) and Gab2 (/) cells were depleted of cytokines Received: February 12, 2002
for 6 hr before cell lysates were prepared for immunoblotting. BCR/ABL- Revised: May 24, 2002
transformed primary B lymphoid cells obtained from in vitro lymphoid trans-
formation assays were lysed and subjected to immunoblot analysis as de- References
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